ALNYLAM PHARMACEUTICALS INC (ALNY) Stock News

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest

$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Jefferies Taps Former Alnylam CEO Maraganore as Senior Adviser

Investment bank Jefferies Financial Group Inc. has hired former Alnylam Pharmaceuticals Inc. Chief Executive Officer John Maraganore as a senior adviser.

Alnylam Pharmaceuticals Larger Than S&P 500 Component United Airlines Holdings

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Alnylam Pharmaceuticals Enters Oversold Territory (ALNY)

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Alnylam to Webcast TTR Investor Day

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Alnylam Stock Soars 65%: Find Out What’s Behind the Gains

Alnylam Pharmaceutical is on the move. In early to mid-2025, the FDA is expected to approve expanded use of a key drug.